CD38 and B-cell chronic lymphocytic leukemia: Hence, targeting CD38 may be a new treatment in CLL, which would result in the loss of both Tregs and Breg-like CLL cells to regulate the tumor micro-environment and promote reconstitution of the immune system (Manna et al., 2020).